WS05.05 Randomised withdrawal of hypertonic saline in those with lower lung function after receiving elexacaftor/tezacaftor/ivacaftor; a sub-study of the SIMPLIFY Trial

Objectives: SIMPLIFY tested withdrawal of hypertonic saline (HS) or dornase alfa for 6 weeks in PwCF taking ETI and showed non-inferiority (compared with continuing HS or dornase alfa) in both lung function and respiratory symptom scores. Inclusion in either trial required ppFEV1 ≥60%, and the mean ppFEV1 was 97%. A pre-planned lower lung function (LLF) sub-study was conducted to test HS withdrawal in PwCF with ppFEV1 of 40–59%, hypothesizing that continuing HS is superior to discontinuing HS with respect to 6-week change in ppFEV1.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Workshops Source Type: research